HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications

International Journal of Gynecological Cancer

Volumn 16, Issue 5, 2006, Pages 1897-1902

  Villella, J A ^a   Cohen, S ^b   Smith, D H ^b   Hibshoosh, H ^b   Hershman, D ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c Hackensack University Medical Center   (United States)

Author keywords

HER 2 neu; HercepTest; Trastuzumab (Herceptin); Uterine papillary serous cancer

Indexed keywords

CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE PROTEIN; PARAFFIN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY CANCER; PAPILLARY CARCINOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; UTERUS CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; RECEPTOR, ERBB-2;

EID: 33749144509     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00664.x     Document Type: Article

References (52)

1. Society AC. Cancer facts and figures. Atlanta: American Cancer Society 2005, p. 21.
2. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
3. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
4. Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-8.
5. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995;14:30-8.
6. Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol 1985;4:279-88.
7. Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol 1993;48:32-7.
8. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
9. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
10. Busse D, Doughty RS, Arteaga CL. HER-2/neu (erbB-2) and the cell cycle. Semin Oncol 2000;27(6 Suppl. 11):3-8, discussion 92-100.
11. Anderson NG, Ahmad T. ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Front Biosci 2002;7:d1926-40.
12. Gal D, Recio FO, Zamurovic D. The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer 1992;69:200-2.
13. Levenback C, Burke TW, Silva E et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992;46:317-21.
14. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993;51:383-9.
15. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
16. Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 2001;82:156-61.
17. Resnik E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1996;62:123-7.
18. Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 1999;73:461-3.
19. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999;74:272-7.
20. Ross JS, Fletcher JA, Bloom KJ et al. HER-2/neu testing in breast cancer. Am J Clin Pathol 2003 Dec; 120 Suppl: S53-71.
21. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25.
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
23. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
24. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
25. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
26. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74.
27. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
28. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-8.
29. Montemurro F, Faggiuolo R, Redana S et al. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005;23:2866-8; discussion 8-9.
30. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
31. Salmon DJ, Leyland-Jones B, Shack S et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER21/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol 1998;17:98a. Abstract 377.
32. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68.
33. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90.
34. Berchuck A, Rodriguez G, Kinney RB et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164(1 Pt 1):15-21.
35. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
36. Slomovitz BM, Broaddus RR, Burke TW et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004;22:3126-32.
37. Santin AD, Bellone S, Gokden M et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271-9.
38. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
39. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-9.
40. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23.
41. Tawfik OW, Kimler BF, Davis M et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 2006;48:258-67.
42. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
43. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
44. Lewis GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
45. Szollosi J, Balazs M, Feuerstein BG, Benz CC, Waldman FM. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 1995;55:5400-7.
46. Kallioniemi OP, Kallioniemi A, Kurisu W et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1992;89:5321-5.
47. Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol 2006;6:2.
48. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
49. Pritchard K, O'Malley FA, Andrulis I et al. Prognostic and predictive value of HER-2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph nodes positive breast cancer (NCIC CTG MA.5) [abstract]. Proc ASCO 2002;21:42a. Abstract 165.
50. Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141-51.
51. Cappuzzo F, Varella-Garcia M, Shigematsu H et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-18.
52. Spigel DR, Burstein HJ. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2003;4:329-37; discussion 38-9.